ClinicalTrials.gg
RecruitingNCT05283044PRISM-POrTALUpdated Nov 6, 2026

Implementing Precision Medicine in cOmmunity HospiTALs

An interventional study of biopsy liquid in Metastatic Cancer, sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 21 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Neoplasm Metastasis by Gustave Roussy, Cancer Campus, Grand Paris — 4 open to participants now, 4 under way, none of them phase 3. Neoplasm Metastasis · Gustave Roussy, Cancer Campus, Grand Paris.

Planned enrollment
Largest of 13
10,000 · median 60
Started
2022
the only one that year
No phase
4 of 14
1 open now
Registered
11th of 14
by date

Among the 14 studies in Neoplasm Metastasis by Gustave Roussy, Cancer Campus, Grand Paris, this one has the largest planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2022, is one of 4 with no phase, and was the 11th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

4 of the 14 studies in Neoplasm Metastasis by Gustave Roussy, Cancer Campus, Grand Paris are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Neoplasm Metastasis by Gustave Roussy, Cancer Campus, Grand Paris, or all of them as a file.
02

Study summary

This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting

Read the detailed description

Patients will be selected to present a metastatic cancer (de novo or relapse after primary tumor treatment) eligible for a first line treatment (chemotherapy, immunotherapy, endocrine therapy or targeted therapy).

All tumor subtype could be enrolled in the study; metastatic prostate cancer must be resistant to castration. Triple negative breast cancer and Hormone receptor positive, Her2-negative metastatic breast cancer resistant to endocrine therapy are eligible to the study.

A plasma sample will be collected at baseline and will be tested for a large panel of gene and MSI status using Next Generation Sequencing (NGS) (cf table). Results will be discussed within a Molecular Tumor Board (MTB) with all declared centers.

03

Conditions studied

  • Metastatic Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if they meet all of the following criteria:

  1. Age ≥ 18 years
  2. Histology: solid malignant tumor
  3. Locally advanced/unresectable and/or (for prostate cancer: castration resistant prostate cancer, for RH+/- breast cancer: prior treatment with endocrine therapy plus anti-CDK4/6 inhibitor)
  4. (ECOG) performance status \< 2
  5. as per criteria
  6. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)
  7. Voluntary signed and dated written prior to any study specific procedure.

Exclusion criteria

Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

  1. Radiological evidence of symptomatic or progressive
  2. Previous or current of others histologies within the last 2 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin and prostate cancer
  3. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol
  4. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent
  5. Minors (Age \< 18 years)
  6. Pregnant or breast-feeding women
  7. Previous enrollment in the present study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10,000 participants (estimated)

Study arms

  • Other
    Biopsy liquid contributive

    Patients presenting for whom ct DNA sequencing

    Biological: biopsy liquid

Interventions

  • Biologicalbiopsy liquid

    Patient performs a blood test at treatment baseline

06

What researchers measure

Primary outcomes

  1. Proportion of patients for whom ctDNA sequencing

    The primary objective of the study will be to evaluate the impact of ctDNA sequencing on the treatment plan of cancer patients managed in satellite centers. This will be performed by estimating the proportion of patients for whom ctDNA sequencing has allowed to propose a systemic treatment that was not considered before the clinician.

    Time frame: 72 months

Secondary outcomes

  1. Utilization rates of molecular profiling information

    The utilization rates of molecular profiling information (including utilization of information for standard regimens or clinical trials of molecularly targeted therapies)

    Time frame: 72 months

  2. Rate of molecular screening failure

    Time frame: 72 months

  3. Relapsed time between liquid biopsy and matched therapy onset

    Time frame: 72 months

  4. Rate of patients presenting targetable alterations

    The rate of patients presenting targetable alterations according to alterations subtypes (copy number/mutation/oncogenic fusions)

    Time frame: 72 months

  5. Utilization rate of tumor mutational burden

    The utilization rate of tumor mutational burden (TMB - based on new generation sequencing panels)

    Time frame: 72 months

  6. Objective Response Rate

    Time frame: 72 months

  7. Overall Survival of patients treated with a therapy matched to a targetable alteration and recommended by the MTB based on the ctDNA sequencing

    Time frame: 72 months

07

Study locations

13 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — no IPD in this study

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Nov 2028, 76 months after the start.

Of 295 non-industry interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 93. This study's planned 76 months is above that.

Counting every sponsor, half of 320 studies reached it within 54 months; a quarter within 28 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 16, 2022
StartActual
Jun 29, 2022
Primary completionEst.
Nov 15, 2028
CompletionEst.
Apr 15, 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05283044
Responsible party
Sponsor
First posted
Mar 16, 2022
Start date
Jun 29, 2022
Primary completion
Nov 15, 2028 (estimated)
Completion
Apr 15, 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

Benjamin Verret, MD
Contact
Benjamin.verret@gustaveroussy.fr
+33 (0)1 42 11 42 11
Antoine Italiano, MD
Contact
antoine.italiano@gustaveroussy.fr
+33 (0)1 42 11 42 11

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion